New gallbladder drug trial: does food change how it works?
NCT ID NCT07594977
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new tablet called 4-MUST in 45 healthy volunteers. Researchers want to see if taking the drug with food changes how much gets into the blood, and how safe and tolerable it is after single and repeated doses. The results will help design future studies for people with chronic cholecystitis (gallbladder inflammation) and biliary dyskinesia (bile duct movement problems).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4-MUST (trimebutine 4-methylumbelliferyl sulfate) tablets
What this could lead to
If successful, this study could help determine the best way to take 4-MUST (with or without food) for future trials in people with gallbladder or bile duct issues.
What could go wrong
This is a very early Phase 1 trial in only 45 healthy volunteers, not patients. It focuses on drug levels and safety, not on treating any disease. The results may not predict how the drug works in people who are actually sick.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY DYSKINESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
I.M. Sechenov First Moscow State Medical University
RECRUITINGMoscow, 119991, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••